Article ISI
JOURNAL FOR IMMUNOTHERAPY OF CANCER  (2020)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Motzer, Robert J.; Melichar, Bohuslav; Gruenwald, Viktor; Ravaud, Alain; Geertsen, Poul F.; Tomita, Yoshihiko; Saggi, Shruti Shally

Abstract

Background The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in the phase 3 CheckMate 214 trial. Survival, response, and safety outcomes with NIVO+IPI versus SUN were assessed after a minimum of 42 months of follow-up.

Más información

Título según WOS: Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Título de la Revista: JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volumen: 8
Número: 2
Editorial: LONDON
Fecha de publicación: 2020
DOI:

10.1136/JITC-2020-000891
Notas: ISI